Conclusions

- Our study suggests that nivolumab and ipilimumab-based therapy is an optimal treatment option for patients with PD-L1 TPS 1-20%.
- The dual group is more effective than the single group in the population with PD-L1 TPS 1-20% (Fig1).
- Dual immune checkpoint blockade has longer PFS and OS in the population with PD-L1 TPS 1-20% than with 21-49% (Fig2).
- The dual group showed no difference in PFS in the PD-L1 negative population compared to the single group but tended to have a longer PFS and OS in the low expression population (Fig5).